Streetwise Reports' Article Archives — February 2023 back to current month (4)
White-label reselling of proven therapeutic compounds and concepts to existing, branded providers offers research companies a way to capture market share without marketing expenses – or other customer-facing costs. Awakn Life Sciences Corp., already a marquee name in rehabilitation clinics across Europe, is also rapidly engaging in this lucrative secondary profit stream.
AI-Infused Telehealth Platform Absorbs New Patients (02/22/2023)
Telemedicine company Reliq Health Technologies Inc., which uses artificial intelligence in its software's algorithms, has gained six new contracts and more than 3,000 new patients.
Biotech Co. Initiates Feasibility Study (02/09/2023)
This morning Awakn Life Sciences announced it had initiated a feasibility study of MDMA leveraging Catalent's proprietary Zydis ODT fast dissolve technology. Read more to learn what this means for the company, why this may be needed, and what experts are saying about Awakn.
Pharmaceutical powerhouse Awakn has been awarded Innovative Licensing and Access Pathway (ILAP) access to UK markets. This classification, equivalent to FDA Breakthrough Therapy designation in the U.S., allows the company to expedite development growth in the region.